Cost-effectiveness of first-line vs third-line ibrutinib in patients with untreated chronic lymphocytic leukemia. uri icon

authors

  • Patel, Kishan K
  • Isufi, Iris
  • Kothari, Shalin
  • Davidoff, Amy J
  • Cary Gross, MD
  • Huntington, Scott F

publication date

  • January 1, 2020

published in